Access the full text.
Sign up today, get DeepDyve free for 14 days.
Anil Sehgal, Mitchel Berger (2000)
Basic concepts of immunology and neuroimmunology.Neurosurgical focus, 9 6
Daehwan Kim, G. Pertea, C. Trapnell, Harold Pimentel, Ryan Kelley, S. Salzberg (2013)
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusionsGenome Biology, 14
Jinkuk Kim, In-Hee Lee, H. Cho, Chul-Kee Park, Yang-Soon Jung, Yanghee Kim, So Nam, Byung Kim, Mark Johnson, D. Kong, H. Seol, Jung-Il Lee, K. Joo, Yeup Yoon, W. Park, Jeongwu Lee, P. Park, D. Nam (2015)
Spatiotemporal Evolution of the Primary Glioblastoma Genome.Cancer cell, 28 3
Susan Chang, Peixin Zhang, J. Cairncross, M. Gilbert, J. Bahary, C. Dolinskas, A. Chakravarti, K. Aldape, E. Bell, D. Schiff, K. Jaeckle, P. Brown, G. Barger, M. Werner-Wasik, H. Shih, D. Brachman, M. Penas-Prado, H. Robins, K. Bélanger, C. Schultz, G. Hunter, M. Mehta (2016)
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813Neuro-Oncology, 19
R. Stupp, Warren Mason, M. Bent, M. Weller, B. Fisher, M. Taphoorn, K. Bélanger, A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, Robert Janzer, Samuel Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. Cairncross, E. Eisenhauer, R. Mirimanoff (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.The New England journal of medicine, 352 10
E. Bouffet, Valérie Larouche, B. Campbell, D. Merico, Richard Borja, M. Aronson, C. Durno, J. Krueger, V. Cabric, V. Ramaswamy, N. Zhukova, G. Mason, R. Farah, S. Afzal, M. Yalon, G. Rechavi, Vanan Magimairajan, M. Walsh, S. Constantini, R. Dvir, R. Elhasid, A. Reddy, M. Osborn, M. Sullivan, J. Hansford, A. Dodgshun, N. Klauber-DeMore, L. Peterson, Sunil Patel, S. Lindhorst, J. Atkinson, Z. Cohen, R. Laframboise, P. Dirks, Michael Taylor, D. Malkin, S. Albrecht, Roy Dudley, N. Jabado, C. Hawkins, A. Shlien, U. Tabori (2016)
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 19
Karan Dixit, P. Kumthekar (2017)
Gene Delivery in Neuro-OncologyCurrent Oncology Reports, 19
B. John, C. Hunter, T. Harris (2014)
Immune Cell Trafficking in the Central Nervous System
D. Reardon, A. Omuro, A. Brandes, J. Rieger, A. Wick, J. Sepúlveda, S. Phuphanich, P. Souza, M. Ahluwalia, M. Lim, G. Vlahović, J. Sampson (2017)
OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143Neuro-oncology, 19
Masamichi Takahashi, G. Valdes, K. Hiraoka, Akihito Inagaki, Shuichi Kamijima, E. Micewicz, H. Gruber, J. Robbins, D. Jolly, W. McBride, K. Iwamoto, N. Kasahara (2014)
Radio-sensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vectorCancer gene therapy, 21
Q. Ostrom, H. Gittleman, Peter Liao, Toni Vecchione-Koval, Yingli Wolinsky, C. Kruchko, J. Barnholtz-Sloan (2017)
CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014Neuro-Oncology, 19
W. Yung, R. Albright, J. Olson, R. Fredericks, K. Fink, M. Prados, M. Brada, A. Spence, R. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. Selker, N. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, V. Levin (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 83
K. Yagiz, Tiffany Huang, Fernando Espinoza, Daniel Mendoza, C. Ibañez, H. Gruber, D. Jolly, J. Robbins (2016)
Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.Neuro-oncology, 18 10
A. Ortega, J. Sarmiento, Diana Ly, M. Nuno, Debraj Mukherjee, K. Black, C. Patil (2016)
Multiple resections and survival of recurrent glioblastoma patients in the temozolomide eraJournal of Clinical Neuroscience, 24
R. Madan, J. Gulley, T. Fojo, W. Dahut (2010)
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.The oncologist, 15 9
J. Mandel, D. Cachia, Diane Liu, Charmaine Wilson, K. Aldape, G. Fuller, J. Groot (2016)
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastomaJournal of Neuro-Oncology, 129
L. Colli, M. Machiela, Timothy Myers, Lea Jessop, Kai Yu, S. Chanock (2016)
Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses.Cancer research, 76 13
(2017)
Regulatory perspective on endpoints for immuno-oncology drug products. Office of New Center for Drug Evaluation and Research, FDA
T. Schumacher, R. Schreiber (2015)
Neoantigens in cancer immunotherapyScience, 348
Q. Ostrom, H. Gittleman, Peter Liao, Chaturia Rouse, Yanwen Chen, J. Dowling, Yingli Wolinsky, C. Kruchko, J. Barnholtz-Sloan (2012)
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.Neuro-oncology, 16 Suppl 4
M. Gustafson, Yi Lin, Kent New, P. Bulur, B. O'neill, D. Gastineau, A. Dietz (2010)
Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.Neuro-oncology, 12 7
R. Weller, Shinya Kida, E. Zhang (1992)
Pathways of Fluid Drainage from the Brain ‐ Morphological Aspects and Immunological Significance in Rat and ManBrain Pathology, 2
J. Ferlay, Hai-rim Shin, F. Bray, D. Forman, C. Mathers, D. Parkin (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 127
T. Cloughesy, J. Landolfi, Daniel Hogan, Stephen Bloomfield, B. Carter, Clark Chen, J. Elder, S. Kalkanis, S. Kesari, A. Lai, I. Lee, L. Liau, T. Mikkelsen, P. Nghiemphu, D. Piccioni, T. Walbert, A. Chu, A. Das, Oscar Diago, D. Gammon, H. Gruber, M. Hanna, D. Jolly, N. Kasahara, David McCarthy, L. Mitchell, Derek Ostertag, J. Robbins, Maria Rodriguez-Aguirre, M. Vogelbaum (2016)
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade gliomaScience Translational Medicine, 8
K. Hiraoka, Akihito Inagaki, Yuki Kato, Tiffany Huang, L. Mitchell, Shuichi Kamijima, Masamichi Takahashi, H. Matsumoto, K. Hacke, C. Kruse, Derek Ostertag, J. Robbins, H. Gruber, D. Jolly, N. Kasahara (2017)
Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunityNeuro-Oncology, 19
J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. Parkin, D. Forman, F. Bray, S. Elser, M. Ervick (2013)
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]
Derek Ostertag, K. Amundson, Fernando Espinoza, B. Martin, T. Buckley, A. Silva, A. Lin, David Valenta, O. Perez, C. Ibañez, Ching-I Chen, P. Pettersson, Ryan Burnett, Veronika Daublebsky, J. Hlavaty, W. Gunzburg, N. Kasahara, H. Gruber, D. Jolly, J. Robbins (2011)
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vectorNeuro-Oncology, 14
W. Wick, A. Brandes, T. Gorlia, M. Bendszus, F. Sahm, W. Taal, M. Taphoorn, J. Dômont, A. Idbaih, M. Campone, P. Clement, R. Stupp, M. Fabbro, E. Rhun, F. Dubois, M. Klein, M. Plattén, M. Weller, V. Golfinopoulos, M. Bent (2016)
EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.Journal of Clinical Oncology, 34
P. Medawar (1948)
Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye.British journal of experimental pathology, 29 1
M. Weller, T. Cloughesy, J. Perry, W. Wick (2013)
Standards of care for treatment of recurrent glioblastoma--are we there yet?Neuro-oncology, 15 1
T. Hodges, Martina Ott, J. Xiu, Z. Gatalica, J. Swensen, Shouhao Zhou, J. Huse, J. Groot, Shulin Li, W. Overwijk, D. Spetzler, A. Heimberger (2017)
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapyNeuro-Oncology, 19
T. Johanns, Christopher Miller, I. Dorward, C. Tsien, E. Chang, A. Perry, R. Uppaluri, Cole Ferguson, R. Schmidt, S. Dahiya, G. Ansstas, E. Mardis, G. Dunn (2016)
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.Cancer discovery, 6 11
H. Friedman, M. Prados, P. Wen, T. Mikkelsen, D. Schiff, L. Abrey, W. Yung, N. Paleologos, M. Nicholas, R. Jensen, J. Vredenburgh, Jane Huang, M. Zheng, T. Cloughesy (2009)
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
M. Plattén, D. Schilling, T. Bunse, F. Sahm, Angela Hueckelhoven, I. Schenkel, S. Stevanović, A. Schmitt, Marion Laumann, J. Steinbach, M. Misch, G. Tabatabai, A. Weyerbrock, O. Schnell, D. Krex, J. Hense, M. Bendszus, A. Deimling, M. Schmitt, W. Wick (2016)
A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).Journal of Clinical Oncology, 34
J. Polívka, J. Polívka, L. Holubec, T. Kubíková, V. Priban, O. Hes, K. Pivovarcikova, I. Třešková (2017)
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.Anticancer research, 37 1
L. Mitchell, Fernando Espinoza, Daniel Mendoza, Yuki Kato, Akihito Inagaki, K. Hiraoka, N. Kasahara, H. Gruber, D. Jolly, J. Robbins (2017)
Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma modelNeuro-Oncology, 19
F. Hodi, W. Hwu, R. Kefford, J. Weber, A. Daud, O. Hamid, A. Patnaik, A. Ribas, C. Robert, T. Gangadhar, A. Joshua, P. Hersey, R. Dronca, R. Joseph, D. Hille, Dahai Xue, Xiaoyun Li, S. Kang, S. Ebbinghaus, A. Perrone, J. Wolchok (2016)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 13
P. Wen, D. MacDonald, D. Reardon, T. Cloughesy, A. Sorensen, E. Galanis, J. Degroot, W. Wick, M. Gilbert, A. Lassman, C. Tsien, T. Mikkelsen, Eric Wong, M. Chamberlain, R. Stupp, K. Lamborn, M. Vogelbaum, M. Bent, Susan Chang (2010)
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 11
D. MacDonald, T. Cascino, S. Schold, J. Cairncross, G. Cairncross (1990)
Response criteria for phase II studies of supratentorial malignant glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8 7
T. Huang, J. Hlavaty, Derek Ostertag, Fernando Espinoza, B. Martin, H. Petznek, Maria Rodriguez-Aguirre, C. Ibañez, N. Kasahara, W. Günzburg, H. Gruber, D. Pertschuk, D. Jolly, J. Robbins (2013)
Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma modelCancer Gene Therapy, 20
Benjamin Plog, M. Nedergaard (2018)
The Glymphatic System in Central Nervous System Health and Disease: Past, Present, and Future.Annual review of pathology, 13
Huixia Zhu, Ye Zhang, Jianfeng Chen, J. Qiu, K-M Huang, M. Wu, Chunlin Xia (2017)
IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are ReducedPLoS ONE, 12
W. Taal, H. Oosterkamp, A. Walenkamp, H. Dubbink, L. Beerepoot, M. Hanse, J. Buter, A. Honkoop, D. Boerman, F. Vos, W. Dinjens, R. Enting, M. Taphoorn, F. Berkmortel, R. Jansen, D. Brandsma, J. Bromberg, I. Heuvel, R. Vernhout, B. Holt, M. Bent (2014)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.The Lancet. Oncology, 15 9
K. Draaisma, M. Wijnenga, Bas Weenink, Ya Gao, M. Smid, P. Robe, M. Bent, P. French (2015)
PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patientsActa Neuropathologica Communications, 3
D. Macdonald (2001)
Temozolomide for recurrent high-grade glioma.Seminars in oncology, 28 4 Suppl 13
H. Vries, J. Kuiper, A. Boer, T. Berkel, D. Breimer (1997)
The blood-brain barrier in neuroinflammatory diseases.Pharmacological reviews, 49 2
V. Perry, P. Andersson (1992)
The inflammatory response in the CNSNeuropathology and Applied Neurobiology, 18
B. Ellingson, P. Wen, T. Cloughesy (2017)
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical TrialsNeurotherapeutics, 14
NG Burnet, SJ Jefferies, RJ Benson, DP Hunt, F. Treasure (2005)
Years of life lost (YLL) from cancer is an important measure of population burden – and should be considered when allocating research fundsBritish Journal of Cancer, 92
C. Trapnell, David Hendrickson, Martin Sauvageau, L. Goff, J. Rinn, L. Pachter (2012)
Differential analysis of gene regulation at transcript resolution with RNA-seqNature Biotechnology, 31
W. Wick, V. Puduvalli, M. Chamberlain, M. Bent, A. Carpentier, L. Cher, W. Mason, M. Weller, Shengyan Hong, L. Musib, A. Liepa, D. Thornton, H. Fine (2010)
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
BackgroundVocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase that, when used in combination with extended-release 5-fluorocytosine (Toca FC), results preclinically in local production of 5-fluorouracil, depletion of immune-suppressive myeloid cells, and subsequent induction of antitumor immunity. Recurrent high-grade glioma (rHGG) patients have a high unmet need for effective therapies that produce durable responses lasting more than 6 months. In this setting, relapse is nearly universal and most responses are transient.MethodsIn this Toca 511 ascending-dose phase I trial (NCT01470794), HGG patients who recurred after standard of care underwent surgical resection and received Toca 511 injected into the resection cavity wall, followed by orally administered cycles of Toca FC.ResultsAmong 56 patients, durable complete responses were observed. A subgroup was identified based on Toca 511 dose and entry requirements for the follow-up phase III study. In this subgroup, which included both isocitrate dehydrogenase 1 (IDH1) mutant and wild-type tumors, the durable response rate is 21.7%. Median duration of follow-up for responders is 35.7+ months. As of August 25, 2017, all responders remain in response and are alive 33.9+ to 52.2+ months after Toca 511 administration, suggesting a positive association of durable response with overall survival.ConclusionsMultiyear durable responses have been observed in rHGG patients treated with Toca 511 + Toca FC in a phase I trial, and the treatment will be further evaluated in a randomized phase III trial. Among IDH1 mutant patients treated at first recurrence, there may be an enrichment of complete responders.
Neuro-Oncology – Oxford University Press
Published: Sep 3, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.